Actinium Pharmaceuticals, Inc. (Delaware)

8.12 USD
+0.12 (+1.50%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Actinium Pharmaceuticals, Inc. (Delaware) stock is up 5.45% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 11 May’s closed higher than April. In the last 3 Unusual Options Trades, there were 3 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 Apr 18:38 15 Nov, 2024 10.00 CALL 200 102
30 Apr 15:27 17 May, 2024 5.00 CALL 100 419
16 May 16:25 17 May, 2024 5.00 CALL 100 318

About Actinium Pharmaceuticals, Inc. (Delaware)

Actinium Pharmaceuticals, Inc. focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning. The company also offers clinical and preclinical development programs that utilize multiple isotopes.

  • HC Wainwright & Co.
    Tue May 21, 06:50
  • Stephens & Co.
    Tue May 14, 05:54
  • HC Wainwright & Co.
    Thu May 2, 13:11